Women's telehealth company Wisp expands into diagnostics with at-home STI testing
Aims to be a one-stop shop for all women's sexual and reproductive health needs
U.S women’s telehealth company Wisp is broadening its sexual and reproductive health solutions with an expansion into the diagnostics space.
Already serving more than 1.5 million customers across the country, the new Wisp At-Home Testing & Follow-Up Care service will provide patients with at-home test kits for various health conditions, enabling them to collect samples and receive results without needing to visit a clinic in person.
“Integrating diagnostics into Wisp’s already comprehensive care offerings was a natural evolution for the company,” said Monica Cepak, Wisp CEO.
“We’re simplifying the path to complete, 360-degree care — making it possible for patients to access testing and treatment from the comfort of home. Our mission has and continues to center around improving accessibility and affordability, which is why our testing kits are at the lowest price point on the market and include a free consultation to ensure every patient receives follow-up care.”
Launching with STI testing
The company launches the new vertical with its Common STI Panel (testing for Chlamydia, Gonorrhea, and Trichomaniasis), 3-Site Panel (testing for Chlamydia and Gonorrhea), and M-Gen Panel (testing for Mycoplasma Genitalium or Mgen).
Wisp members in all 50 states simply provide swab and urine samples, ship them back to a CLIA/CAP accredited lab using the prepaid label, and receive results in 3-5 business days.
Chlamydia, Gonorrhea, and Trichomoniasis are three of the most common STIs, especially for women under 25. In Wisp’s latest survey, 62 percent of its patients expressed interest in STI testing, with its STI, STD and Herpes categories up 40 percent year-over-year.
“At Wisp, we’re committed to breaking down barriers in women’s healthcare. As providers, we see firsthand how access to reliable, discreet diagnostics—paired with fast, evidence-based treatment—can truly change lives,” said Dr. Jillian LoPiano, MD, MPH, FACOG.
“By partnering with labs that meet the highest clinical standards for accuracy, and offering streamlined access to treatment when it’s needed, we’re not just improving convenience—we’re helping to destigmatize sexual health and empower patients to take control of their care with confidence.”
Continued expansion
The company’s move into diagnostics follows launches of its fertility and weight care verticals, as well as the expansion of its menopause category.
Wisp plans to further expand its diagnostics offerings with new at-home testing kits focused on hormonal health later this year, adding in-home blood draw services to expand its fertility and menopause verticals specifically.